NCT00678301View on ClinicalTrials.gov

Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™

PHASE3CompletedINTERVENTIONAL
Enrollment

365

Participants

Timeline

Start Date

June 18, 2008

Primary Completion Date

November 9, 2009

Study Completion Date

December 10, 2009

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

GSK Biologicals' Synflorix™

3 IM doses.

BIOLOGICAL

GSK Biologicals' Polio Sabin™

3 oral doses

BIOLOGICAL

GSK Biologicals' Zilbrix™ Hib

3 IM doses.

Trial Locations (2)

Unknown

GSK Investigational Site, Bamako

P.M.B. 21266

GSK Investigational Site, Ikeja / Lagos

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00678301 - Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™ | Biotech Hunter | Biotech Hunter